Capstone Headwaters Reports: Pharmaceutical Outsourcing M&A Demand Remains Robust Despite COVID-19 Disruption

August 14, 2020

Boston, MA – Capstone Headwaters released its Pharmaceutical Outsourcing report today, reporting that despite COVID-19 induced disruption, merger and acquisition activity has remained robust in the Pharmaceutical Outsourcing industry with 37 transactions announced or completed in year-to-date (YTD) 2020, slightly outpacing the 36 transactions in YTD 2019.  Contract development and manufacturing organizations (CDMOs) and lab & testing providers have comprised the majority of acquisitions YTD at 35.1% and 29.7%, respectively.

The pandemic has emphasized the need for the industry to rethink its reliance on offshore manufacturing and complex global supply chains, as well as how to utilize technology to adopt a more decentralized approach to conducting clinical trials.

To access the full Pharmaceutical Outsourcing report, click here


Capstone Headwaters is one of the largest and most active independent investment banking firms in the United States.  The firm has a rich 18+ year history of achieving extraordinary results for middle market entrepreneurs, business owners, investors, and creditors.  The firm offers a fully integrated suite of corporate finance services, including merger & acquisition, debt & equity placement, ESOP advisory, corporate restructuring, valuation & fairness opinion, and financial advisory services.  Headquartered in Boston, Capstone Headwaters has over 170 professionals across 17 offices in the U.S. with 16 dedicated industry groups. Capstone has been recognized consistently as one of the top investment banks to work for and “U.S. Middle Market Firm of the Year.” For more information, visit

For More Information Contact the Key Report Contributors:

Eric Williams
Managing Director                                                

Mark Surowiak